推荐产品
生物源
mouse
共軛
unconjugated
抗體表格
ascites fluid
抗體產品種類
primary antibodies
無性繁殖
FLT-11, monoclonal
分子量
antigen 160-200 kDa
包含
15 mM sodium azide
物種活性
human
技術
immunocytochemistry: suitable
immunohistochemistry (frozen sections): suitable
immunoprecipitation (IP): suitable
indirect ELISA: suitable
western blot: 1:500 using VEGF Receptor-1 (Flt-1)/Fc Chimera human recombinant
同型
IgG1
UniProt登錄號
運輸包裝
dry ice
儲存溫度
−20°C
目標翻譯後修改
unmodified
基因資訊
human ... FLT1(2321)
一般說明
Vascular Endothelial Growth Factor Receptor-2 (VEGF R2) is a 160-200kD protein that belongs to protein kinase superfamily and is expressed mainly on the surface of various endothelial cells. It plays a pivotal role in the regulation of angiogenesis, cell migration, cell survival and cancer cell invasion. ASV derived from VEGF receptor type 1 serve as a potential therapeutics for rheumatoid arthritis. Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1antibody can be used in western blotting (diluted 1:500) using VEGF Receptor-1 (Flt-1)/Fc Chimera human recombinant. It can also be used in indirect ELISA. Mouse anti-Vascular Endothelial Growth Factor Receptor-1antibody reacts specifically with an epitope within amino acids 1-251 of the extracellular domain of human VEGF Receptor-1 but not with VEGF Receptor-2 (KDR). The product has shown cross reactivity with the mouse Flt1 receptor.
Vascular endothelial growth factor (VEGF) is also called vasculotropin (VAS) and vascular permeability factor (VPF). It is a homodimeric heparin-binding glycoprotein.
特異性
Mouse monoclonal clone FLT-11 anti-VEGF R-1 antibody reacts specifically with the extracellular domain of human VEGF Receptor-1. The epitope recognized by the antibody resides within amino acid residues 1-251 of the VEGF Receptor-1 molecule. The product does not recognize VEGF Receptor-2 (KDR).
免疫原
recombinant human VEGF-1 receptor.
應用
Monoclonal Anti-Vascular Endothelial Growth Factor Receptor-1 antibody can be used in several immunochemical assays like immunohistochemistry, immunocytochemistry and immunoprecipitation for the localization of VEGF-R1.
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
儲存類別代碼
10 - Combustible liquids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Augustine Rajakumar et al.
Hypertension (Dallas, Tex. : 1979), 59(2), 256-264 (2012-01-05)
The cardinal manifestations of the pregnancy-specific disorder preeclampsia, new-onset hypertension, and proteinuria that resolve with placental delivery have been linked to an extracellular protein made by the placenta, soluble fms-like tyrosine kinase 1 (sFlt1), that injures the maternal vasculature. However
Oliver Krysiak et al.
Circulation research, 97(12), 1253-1261 (2005-11-05)
Neutrophil activation and increased migration is associated with preeclampsia and is resolved after delivery. Preeclampsia is an inflammatory disorder where altered levels of vascular endothelial growth factor (VEGF) and the circulating soluble fms-like tyrosine kinase 1 (sFlt-1) have a pathogenic
Anti-VEGF therapy in ophthalmology: a qualitative analysis of transformative drug development
Caplan ES, et al.
Drug Discovery Today, 21(6), 1019-1026 (2016)
Paul-Eduard Neagoe et al.
The Journal of biological chemistry, 280(11), 9904-9912 (2005-01-08)
We previously reported that vascular endothelial growth factor (VEGF)-A(165) inflammatory effect is mediated by acute platelet-activating factor synthesis from endothelial cells upon the activation of VEGF receptor-2 (VEGFR-2) and its coreceptor, neuropilin-1 (NRP-1). In addition, VEGF-A(165) promotes the release of
Tracey L Weissgerber et al.
The Journal of clinical endocrinology and metabolism, 99(3), 978-987 (2014-01-16)
Research examining the source of excess soluble fms-like tyrosine kinase 1 (sFLT1) in preeclampsia has focused on the placenta. The potential contribution of the releasable store of sFLT1 in the systemic vasculature is unknown. We asked whether the nonplacental releasable
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门